{
    "Trade/Device Name(s)": [
        "ARCHITECT iCarbamazepine",
        "ARCHITECT iCarbamazepine Calibrator Kit"
    ],
    "Submitter Information": "Abbott Laboratories Diagnostics Division",
    "510(k) Number": "K103627",
    "Predicate Device Reference 510(k) Number(s)": [
        "K935374"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KLT",
        "DLJ",
        "DKB"
    ],
    "Summary Letter Date": "October 12, 2011",
    "Summary Letter Received Date": "October 13, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3645",
        "21CFR862.3200"
    ],
    "Regulation Name(s)": [
        "Carbamazepine test system",
        "Calibrators, Drug Specific"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "tdm"
    ],
    "Analyte(s)": [
        "Carbamazepine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "Sodium heparin tube",
        "Dipotassium EDTA tube",
        "Sodium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT iCarbamazepine CMIA for quantitative measurement of carbamazepine in serum or plasma",
    "Indications for Use Summary": "Quantitative measurement of carbamazepine in human serum or plasma on the ARCHITECT i System to monitor therapy levels",
    "fda_folder": "Toxicology"
}